據彭博新聞社報導，輝瑞在與諾和諾德的競購戰中提高了對美塞拉的報價

路透中文

2025/11/08

據彭博新聞社報導，<a href="https://laohu8.com/S/PFE">輝瑞</a>在與<a href="https://laohu8.com/S/NVO">諾和諾德</a>的競購戰中提高了對美塞拉的報價

路透11月8日 - 據彭博新聞社周五報導，輝瑞PFE.N已向肥胖症藥物開發商美塞拉MTSR.O提交了一份更誘人的出價，因為輝瑞與競爭對手諾和諾德NOVOb.CO的爭鬥正在升級。

彭博社援引熟悉內情的人士的話報導說，輝瑞的新報價提高了早些時候提出的每股86.20美元（包括里程碑付款）的建議。

路透無法立即覈實彭博社的報導。

就在總部位於紐約的輝瑞公司於周三晚些時候與這家丹麥製藥商之前提出的100億美元收購方案相匹配後數小時，諾和諾德於周四提高了對這家美國生物技術公司的收購報價 (link)。

(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581938858"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581938858\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581938858?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-08 08:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581938858","market":"us","top_or_hot":-1,"title":"據彭博新聞社報導，輝瑞在與諾和諾德的競購戰中提高了對美塞拉的報價","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>據彭博新聞社報導，<a href=\"https://laohu8.com/S/PFE\">輝瑞</a>在與<a href=\"https://laohu8.com/S/NVO\">諾和諾德</a>的競購戰中提高了對美塞拉的報價</title></head><body><p>\n<span>路透11月8日</span><span> - </span>據彭博新聞社周五報導，輝瑞<span>PFE.N</span>已向肥胖症藥物開發商美塞拉<span>MTSR.O</span>提交了一份更誘人的出價，因為輝瑞與競爭對手諾和諾德<span>NOVOb.CO</span>的爭鬥正在升級。</p><p>彭博社援引熟悉內情的人士的話報導說，輝瑞的新報價提高了早些時候提出的每股86.20美元（包括里程碑付款）的建議。</p><p>路透無法立即覈實彭博社的報導。</p><p>就在總部位於紐約的輝瑞公司於周三晚些時候與這家丹麥製藥商之前提出的100億美元收購方案相匹配後數小時，諾和諾德於周四提高了對這家美國<a href=\"https://laohu8.com/S/000504\">生物</a>技術公司的收購報價 (<span>link</span>)。</p><p>(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>據彭博新聞社報導，輝瑞在與諾和諾德的競購戰中提高了對美塞拉的報價</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n據彭博新聞社報導，輝瑞在與諾和諾德的競購戰中提高了對美塞拉的報價\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2025-11-08 08:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>據彭博新聞社報導，<a href=\"https://laohu8.com/S/PFE\">輝瑞</a>在與<a href=\"https://laohu8.com/S/NVO\">諾和諾德</a>的競購戰中提高了對美塞拉的報價</title></head><body><p>\n<span>路透11月8日</span><span> - </span>據彭博新聞社周五報導，輝瑞<span>PFE.N</span>已向肥胖症藥物開發商美塞拉<span>MTSR.O</span>提交了一份更誘人的出價，因為輝瑞與競爭對手諾和諾德<span>NOVOb.CO</span>的爭鬥正在升級。</p><p>彭博社援引熟悉內情的人士的話報導說，輝瑞的新報價提高了早些時候提出的每股86.20美元（包括里程碑付款）的建議。</p><p>路透無法立即覈實彭博社的報導。</p><p>就在總部位於紐約的輝瑞公司於周三晚些時候與這家丹麥製藥商之前提出的100億美元收購方案相匹配後數小時，諾和諾德於周四提高了對這家美國<a href=\"https://laohu8.com/S/000504\">生物</a>技術公司的收購報價 (<span>link</span>)。</p><p>(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0321505439.SGD","symbol_name":"Schroder ISF Global Dividend Maximiser A Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251108:nL4T3WK00V:1","article_id":"2581938858","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581938858","pubTimestamp":1762563485,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"路透11月8日 - 據彭博新聞社周五報導，輝瑞PFE.N已向肥胖症藥物開發商美塞拉MTSR.O提交了一份更誘人的出價，因為輝瑞與競爭對手諾和諾德NOVOb.CO的爭鬥正在升級。彭博社援引熟悉內情的人士的話報導説，輝瑞的新報價提高了早些時候提出的每股86.20美元的建議。路透無法立即核實彭博社的報導。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4139":"生物科技","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4585":"ETF&股票定投概念","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SG9999001176.USD":"United Global Healthcare Acc USD","BK4592":"伊斯兰概念","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4588":"碎股","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4007":"制药","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","MTSR":"Metsera Inc.","BK4581":"高盛持仓","BK4599":"减肥药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","PFE":"辉瑞","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","BK4534":"瑞士信贷持仓","LU0234572021.USD":"高盛美国核心股票组合Acc"},"translate_title":"According to Bloomberg News, Pfizer raises its offer for Mesera in bidding war with Novo Nordisk","themeId":"14a71f61cb92b2ae51e4a7c3aa48f71f","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9,"MTSR":0.9},"content_text":"據彭博新聞社報導，輝瑞在與諾和諾德的競購戰中提高了對美塞拉的報價\n路透11月8日 - 據彭博新聞社周五報導，輝瑞PFE.N已向肥胖症藥物開發商美塞拉MTSR.O提交了一份更誘人的出價，因為輝瑞與競爭對手諾和諾德NOVOb.CO的爭鬥正在升級。彭博社援引熟悉內情的人士的話報導説，輝瑞的新報價提高了早些時候提出的每股86.20美元（包括里程碑付款）的建議。路透無法立即核實彭博社的報導。就在總部位於紐約的輝瑞公司於周三晚些時候與這家丹麥製藥商之前提出的100億美元收購方案相匹配後數小時，諾和諾德於周四提高了對這家美國生物技術公司的收購報價 (link)。(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}